I have received a number of e-mails from men who are both frustrated that Provenge is not yet approved and who are frustrated that even when approved they will not qualify to get the treatment. I understand the frustration and feel the same way. The first question is will the FDA approve Provenge? Only time [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
Prior to the AUA meeting Dendreon released the following to its investors. We will now wait to see what transpires at the AUA meeting which is scheduled to be held in one and a half hours from my posting this. Joel T Nowak MA, MSW – Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival [...]
I don't know about you, but I am waiting very anxiously for today's presentation at the AUA conference from Dendreon about Provenge. It is an absolute shame that we have been put into the position that we needed to wait for more men to die before moving ahead. I am concerned that all of the [...]
As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]
What great news has greeted us today. We can now hope that the FDA will quickly approve Provenge and we can get this sorely needed treatment ASAP. If Provenge gets approval from the FDA it will be the first cancer vaccine ever approved. Sadly it will be only the second approved treatment for prostate cancer! [...]
At 9 am this morning, Dendreon Corporation (Nasdaq: DNDN) announced the long awaited interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B). The clinical trial is designed to assess the safety and efficacy of the investigational active cellular immunotherapy Provenge® (sipuleucel-T) in men with metastatic [...]
